Colin C. Edgerton, MD, discusses key considerations for utilizing biosimilars in the bone health treatment landscape.
*Content was developed independently by The Center for Biosimilars® and supported by Sandoz.
Where clinical, regulatory, and economic perspectives converge—sign up for Center for Biosimilars® emails to get expert insights on emerging treatment paradigms, biosimilar policy, and real-world outcomes that shape patient care.